HEALTH OF WOMAN. 2017.2(118):55–60; doi 10.15574/HW.2017.118.55

Godlevskaya N. A., Starover A. V.
Vinnitsa national medical University M. I. Pirogov

The objective: to study the effectiveness of topical vaginal suppositories Proteflazid® in the form of monotherapy for CIN-the I-II, caused by the human papilloma virus (HPV).

Patients and methods. The study involved 50 women with cervical pathology caused by various strains of human papillomavirus (HPV). All the women were examined and treated in Vinnytsia city clinical hospital № 1. PAP test based on liquid-based cytology, determining proliferation markers HPV genotyping quantitative estimation, determination of the status of the vagina biocenosis bacterioscopy vaginal discharge performed in the laboratory Synevo.

Results. Own clinical experience vaginal suppositories Proteflazid® as monotherapy for the treatment of cervical intraepithelial neoplasia mild to moderate from HPV infection, the complex evaluation of clinical efficacy based on the study of patients complaints, PAP-test based on liquid-based cytology, proliferation markers p16 and Ki- 67, viral load, colposcopy and results of histological examination of altered cervical sites showed a positive therapeutic effect with suppositories, which resulted in 96% of women achieved complete regression of disease, and 4% marked shift in the CIN-II CIN-I.

Conclusion. The positive effect of the drug on the state of the vagina Proteflazid® microbiocenosis, good tolerability, ease of use and lack of side effects give reason for its use in the health care system.

Key words: CIN-I-II, papillomavirus infection, suppositories Proteflazid®.

REFERENCES

1. Kaminskiy VV, Shalko MN, Vorobeva LI, Romaschenko OV, Grinevich AI. 2015. ProteflazId®: spetsificheskaya aktivnost v doklinicheskih issledovaniyah, effektivnost i bezopasnost primeneniya v klinicheskoy praktike pri zabolevaniyah, vyizvannyih virusom papillomyi cheloveka (sistematicheskiy obzor). Zdorove zhenschiny 3(99):122–132.

2. Godlevska NA, Starover AV. 2012. Dosvid vikoristannya preparatu Proteflazid® v likuvanni patologiyi shiyki matki, asotsiyovanoyu z papilomavirusnoyu infektsieyu. Visnik Vinnitskogo derzhavnogo medichnogo universitetu 16;1:91–96.

3. Vorobyova LI. 2015. Papilomavirusna infektsiya: aktualna problema suchasnoyi ginekologiyi. Zdorove zhenshchiny 3(99):21–24.

4. Suslikova LV, Boris OM, Sumenko VV, Kaminskiy AV, Serbenyuk AV. 2009. Efektivnist zastosuvannya ta perenosimist imunomodulyatoriv u zhinok iz papilomavirusnoyu infektsieyu, poednanoyu z peredpuhlinnimi protsesami shiyki matki ta urogenitalnoyu mikst-infektsieyu. Zdorove zhenshchiny 4(40):140–146.

5. Kartashov SM, Beloded OA. 2009. Analiz effektivnosti deystviya immunomodulyatorov, ispolzuemyih v lechenii papillomavirusnoy infektsii. Zdorove zhenschiny 4(40):40–41.